The role of the von Hippel-Lindau tumor suppressor protein (pVHL) in kidney cancer has provided a rationale for treating this disease with hypoxia-inducible factor (HIF) antagonists. In this issue, Simon and coworkers show that the molecular signature of VHL−/− kidney cancers is profoundly influenced by whether they produce both HIF2α and HIF1α or HIF2α alone
Kidney cancer affects over 7000 people each year in the UK and its incidence is rising. The majority...
Patients with Von Hippel-Lindau (VHL) disease develop multiple, synchronous or metachronous clear ce...
Studies during the past two decades have shown that kidney cancer is not a single disease; it is mad...
The von Hippel-Lindau tumor suppressor, pVHL, is a key player in one of the best characterized hypox...
Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene product pVHL is the cause of inhe...
AbstractInactivation of the von Hippel-Lindau tumor suppressor gene is linked to the development of ...
The basic biology underlying the development of clear-cell renal cell carcinoma (ccRCC) is criticall...
Copyright: © Sourbier et al. This is an open-access article distributed under the terms of the Crea...
Over 65,000 Americans are diagnosed with kidney cancer each year and nearly 13,000 die of this disea...
Objectives: The most frequent genomic abnormality in clear cell renal cell carcinoma (cc-RCC) is ina...
CONTEXT Renal cancer is a common urologic malignancy, and therapeutic options for metastatic diseas...
The von Hippel-Lindau (VHL) tumor suppressor gene is mutated as an early event in almost all cases o...
Renal cell carcinoma (RCC) accounts for approximately 58,000 new cases and over 13,000 deaths annual...
AbstractLoss of von Hippel–Lindau protein (pVHL) is known to contribute to the initiation and progre...
International audienceVon Hippel–Lindau (VHL) disease is a rare autosomal dominant syndrome (1/36,00...
Kidney cancer affects over 7000 people each year in the UK and its incidence is rising. The majority...
Patients with Von Hippel-Lindau (VHL) disease develop multiple, synchronous or metachronous clear ce...
Studies during the past two decades have shown that kidney cancer is not a single disease; it is mad...
The von Hippel-Lindau tumor suppressor, pVHL, is a key player in one of the best characterized hypox...
Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene product pVHL is the cause of inhe...
AbstractInactivation of the von Hippel-Lindau tumor suppressor gene is linked to the development of ...
The basic biology underlying the development of clear-cell renal cell carcinoma (ccRCC) is criticall...
Copyright: © Sourbier et al. This is an open-access article distributed under the terms of the Crea...
Over 65,000 Americans are diagnosed with kidney cancer each year and nearly 13,000 die of this disea...
Objectives: The most frequent genomic abnormality in clear cell renal cell carcinoma (cc-RCC) is ina...
CONTEXT Renal cancer is a common urologic malignancy, and therapeutic options for metastatic diseas...
The von Hippel-Lindau (VHL) tumor suppressor gene is mutated as an early event in almost all cases o...
Renal cell carcinoma (RCC) accounts for approximately 58,000 new cases and over 13,000 deaths annual...
AbstractLoss of von Hippel–Lindau protein (pVHL) is known to contribute to the initiation and progre...
International audienceVon Hippel–Lindau (VHL) disease is a rare autosomal dominant syndrome (1/36,00...
Kidney cancer affects over 7000 people each year in the UK and its incidence is rising. The majority...
Patients with Von Hippel-Lindau (VHL) disease develop multiple, synchronous or metachronous clear ce...
Studies during the past two decades have shown that kidney cancer is not a single disease; it is mad...
DOI
Add to ORKG